Gilead clarifies position on Cipla’s sub-licensing effort for remdesivir, the investigational antiviral in the global spotlight as a potential treatment for COVID-19.
Remdesivir licensing action may not be over yet, at least based on goings-on in the Indian market.
Gilead Sciences Inc. has now indicated that licensees of the antiviral don’t have a completely free hand to sub-license the drug to another player, without prior intimation to it. This against the backdrop of news that remdesivir licensee Cipla Ltd
Public Company Edition: With fewer follow-on offerings, drug developers are pursuing other options. Axsome accessed up to $570m in debt, Evolus obtained $250m in a new credit facility and Abeona raised $155m from a PRV sale, but Apimeds was able to execute a small $13.5m IPO.
CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.
As CEO Anderson backs high prices for innovative drugs in Europe
Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.
CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.
As CEO Anderson backs high prices for innovative drugs in Europe
Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.
